AC Immune S.A.
NASDAQ:ACIUBiotechnology
+$0.04 today
- Market cap
- $213.72M
- Beta
- 1.56
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.67
Volume 0.08M
Average 0.32M
ACIU Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
AC Immune S.A.NASDAQ: ACIU
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of CHF 15.91M fell 21.9% year over year, behind the -14.4% change in trailing-twelve-month operating expenses. Sequentially, it rose 7.9% from the prior quarter. Over 3 fiscal years it compounded at -1.1% a year.
Context
- Operating expenses amounted to 2027.3% of revenue in FY2025, up 1964.6 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -21.9% toward the trailing-twelve-month pace of -14.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
CHF · from the income statement
- Latest · FY2025
- 72.44M CHF
- Year-over-year change
- +323.2%
- 4-year CAGR
- -2.1%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.44M | +323.2% |
| FY2024 | 2024-12-31 | 17.12M | +23.9% |
| FY2023 | 2023-12-31 | 13.82M | -81.5% |
| FY2022 | 2022-12-31 | 74.78M | -5.4% |
| FY2021 | 2021-12-31 | 79.01M | — |
Operating Expenses vs competitors
How ACIU compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -14.4% is the 6th highest of 10, against a peer median of -11.1%.
- Operating expenses amounts to 1849.0% of revenue for ACIU, versus a peer median of 7543.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $203.15M USD | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $189.56M USD | -47.4% | -10.9% | 611487.1% | |
| LTM Mar 2026 | $150.13M USD | -11.1% | -27.1% | 69.9% | |
| LTM Mar 2026 | $101.75M USD | +11.1% | -1.4% | 149.4% | |
| LTM Mar 2026 | $87.2M USD | — | +16.9% | 9463.1% | |
| LTM Mar 2026 | CHF 68.45M CHF | -14.4% | -1.1% | 1849.0% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $66.77M USD | +256.3% | +44.2% | — |
| LTM Mar 2026 | $46.29M USD | +25.4% | +8.5% | — | |
| LTM Mar 2026 | $37.72M USD | -21.8% | -10.5% | 7543.6% | |
| LTM Mar 2026 | $28.32M USD | -53.7% | -17.4% | — | |
| LTM Mar 2026 | -$55.19M USD | -179.1% | +31.6% | — | |
| Peer median (excluding ACIU) | — | -11.1% | +3.6% | 7543.6% | |
Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 3.94M | 14.8M | 27.31M | 3.57M |
| Cost of Revenue | 0 | 0 | 54.61M | 62.57M | 0 |
| Gross Profit | 0 | 3.94M | (39.81M) | (35.26M) | 3.57M |
| Gross Margin | — | 100.0% | -268.9% | -129.1% | 100.0% |
| Research & Development | 62.28M | 60.34M | 54.61M | 62.57M | 56.44M |
| Selling, General & Admin | 10.88M | 9.58M | 10.58M | 11.43M | 11.65M |
| Operating Expenses | 79.01M | 74.78M | 13.82M | 17.12M | 72.44M |
| Depreciation & Amortization | 2.41M | 2.36M | 2.22M | 2.16M | 2.5M |
| EBITDA | (70.01M) | (68.03M) | (51.83M) | (48.62M) | (67.75M) |
| EBITDA Margin | — | -1728.7% | -350.2% | -178.0% | -1896.2% |
| Operating Income | (79.01M) | (70.85M) | (53.62M) | (52.38M) | (68.86M) |
| Operating Margin | — | -1800.4% | -362.3% | -191.8% | -1927.3% |
| Interest Income | 6.49M | 69K | 1.04M | 3.2M | 1.87M |
| Interest Expense | 581K | 355K | 176K | 133K | 191K |
| Other Income / Expenses | 6.02M | 107K | (599K) | 1.47M | (1.58M) |
| Income Before Tax | (72.99M) | (70.74M) | (54.22M) | (50.91M) | (70.45M) |
| Pre-Tax Margin | — | -1797.7% | -366.3% | -186.4% | -1971.6% |
| Income Tax Expense | 3K | 13K | 10K | 3K | 0 |
| Net Income | (73M) | (70.75M) | (54.23M) | (50.92M) | (70.45M) |
| Net Margin | — | -1798.0% | -366.4% | -186.4% | -1971.6% |
| EPS (Basic) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| EPS (Diluted) | (0.97) | (0.85) | (0.64) | (0.51) | (0.70) |
| Weighted Avg Shares | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
| Weighted Avg Shares (Diluted) | 74.95M | 83.55M | 84.69M | 99.69M | 100.75M |
AC Immune S.A.
NASDAQ:ACIU
Intrinsic Alpha fair value
Locked
Current Price
$2.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.